Evidence map›Paper›PMID 36922542›Full record

ArticleCommunications medicine2023

Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults.

Amy C Thomas, Elizabeth Oliver, Holly E Baum, Kapil Gupta, Kathryn L Shelley, Anna E Long, Hayley E Jones, Joyce Smith, Benjamin Hitchings, Natalie di Bartolo and 31 more

Open access · goldFull text read
In one paragraph

Article in Communications medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 6 institutions in 2 countries.

Amy C ThomasPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. amyc.thomas@bristol.ac.uk.ORCID http://orcid.org/0000-0002-2658-4126
Elizabeth OliverBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-1211-1942
Holly E BaumBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Kapil GuptaSchool of Biochemistry, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-2115-3503
Kathryn L ShelleySchool of Biochemistry, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0003-2206-7778
Anna E LongTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Hayley E JonesPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Joyce SmithBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-0315-8714
Benjamin HitchingsBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-5248-9061
Natalie di BartoloSchool of Biochemistry, University of Bristol, Bristol, UK.
Kate VasileiouSchool of Biochemistry, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-1878-4603
Fruzsina RabiSchool of Biochemistry, University of Bristol, Bristol, UK.
Hanin AlamirBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Malak EghleilibBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Ore FrancisBristol Veterinary School, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0003-2678-917X
Jennifer OliverBristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.
Begonia Morales-AzaBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Ulrike ObstSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Debbie ShattockBristol Bioresource Laboratories, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Rachael BarrBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Lucy CollingwoodBristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.
Kaltun DualeBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-7126-5319
Niall GraceBristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.
Guillaume Gonnage LiveraBristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.
Lindsay BishopBristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.
Harriet DowningNIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.
Fernanda RodriguesHospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Nicholas TimpsonPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-7141-9189
Caroline L ReltonMRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Bristol, UK.ORCID http://orcid.org/0000-0003-2052-4840
Ashley ToyeSchool of Biochemistry, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0003-4395-9396
Derek N WoolfsonSchool of Biochemistry, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-0394-3202
Imre BergerMax Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-7518-9045
Anu GoenkaBristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Andrew D DavidsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Kathleen M GillespieTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Alistair J K WilliamsTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Mick BaileyBristol Veterinary School, University of Bristol, Bristol, UK.
Ellen Brooks-PollockPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-5984-4932
Adam Finn *Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Alice Halliday *Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
CoMMinS Study Team
University of Bristol · GBBristol Royal Hospital for Children · GBAt Bristol · GBHospitais da Universidade de Coimbra · PTMRC Epidemiology Unit · GBUniversity Hospitals Bristol NHS Foundation Trust · GB

Funding

RCUK | Medical Research Council (MRC) MC/PC/19067RCUK | Medical Research Council (MRC) MR/V028545/1RCUK | Medical Research Council (MRC) MR/V038613/1Wellcome TrustWellcome Trust (Wellcome) 202802/Z/16/ZWellcome Trust (Wellcome) 217509/Z/19/Z
6 · The paper itself

Abstract

backgroundSaliva is easily obtainable non-invasively and potentially suitable for detecting both current and previous SARS-CoV-2 infection, but there is limited evidence on the utility of salivary antibody testing for community surveillance.

methodsWe established 6 ELISAs detecting IgA and IgG antibodies to whole SARS-CoV-2 spike protein, to its receptor binding domain region and to nucleocapsid protein in saliva. We evaluated diagnostic performance, and using paired saliva and serum samples, correlated mucosal and systemic antibody responses. The best-performing assays were field-tested in 20 household outbreaks.

resultsWe demonstrate in test accuracy (N = 320), spike IgG (ROC AUC: 95.0%, 92.8-97.3%) and spike IgA (ROC AUC: 89.9%, 86.5-93.2%) assays to discriminate best between pre-pandemic and post COVID-19 saliva samples. Specificity was 100% in younger age groups (0-19 years) for spike IgA and IgG. However, sensitivity was low for the best-performing assay (spike IgG: 50.6%, 39.8-61.4%). Using machine learning, diagnostic performance was improved when a combination of tests was used. As expected, salivary IgA was poorly correlated with serum, indicating an oral mucosal response whereas salivary IgG responses were predictive of those in serum. When deployed to household outbreaks, antibody responses were heterogeneous but remained a reliable indicator of recent infection. Intriguingly, unvaccinated children without confirmed infection showed evidence of exposure almost exclusively through specific IgA responses.

conclusionsThrough robust standardisation, evaluation and field-testing, this work provides a platform for further studies investigating SARS-CoV-2 transmission and mucosal immunity with the potential for expanding salivo-surveillance to other respiratory infections in hard-to-reach settings.

Identifiers

PMID36922542
PMCPMC10016188
OpenAlexW4324356854

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read195
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.